

Overview

Stellar Biotechnologies, Inc. is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Management Team

Frank Oakes

Chairman of the Board, President & Chief Executive Officer

Kathi Niffenegger, CPA

Chief Financial Officer & Corporate Secretary

Gregory T. Baxter, PhD

Executive Vice President, Corporate Development

Gary Koppenjan

Senior Director, Investor Relations and Communications

Recent News

Tuesday, February 05, 2019 - 04:20 PM

Stellar Biotechnologies Reports First Quarter Financial Results

Friday, November 30, 2018 - 07:30 AM

Stellar Biotechnologies Reports Fiscal Year 2018 Financial Results

Wednesday, October 31, 2018 - 07:30 AM

Stellar Biotechnologies to Present at BlueTech Summit

Wednesday, September 05, 2018 - 07:30 AM

Stellar Biotechnologies to Supply KLH to National Institutes of Health


Tuesday, August 28, 2018 - 07:30 AM

Stellar Biotechnologies to Present at H. C. Wainwright Global Investment Conference

Contact Information

Stellar Biotechnologies, Inc. 332 East Scott Street Port Hueneme, CA 93041

Nasdaq: SBOT



Share Price	\$1.17
Volume	29.78k
Shares Outstanding	5,330,715
Market Cap	\$6.24m
52 Week High	\$7.63
52 Week Low	\$0.75

as of 02/20/2019

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.